The Pfenex Expression Technology platform employs a revolutionary approach to recombinant protein production. Pfenex has developed one of the most comprehensive expression technology platforms through the engineering and banking of over 150 unique host strain phenotypes and over 100 pre-constructed rapid cloning vectors based on Pseudomonas fluorescens. This comprehensive toolbox is complemented by a high throughput, robotically enabled combinatorial screening approach that enables unprecedented speed and success rate in identifying a production strain capable of producing high titers of high quality protein. The capability is supported by a word class analytical capability that ensures high quality and targeted process optimization. The Pfenex Expression Technology platform is extremely versatile and has routinely demonstrated its ability to successfully produce a broad range of therapeutic and vaccine candidates, from peptides to large, complex proteins.
The institutional knowledge possessed by the Pfenex scientific team which has been accumulated over the past 17 years and over 60 partnerships, including with 12 of the 15 top pharmaceutical companies in the world, is leveraged on every product develop program.
Rapid, high-quality, high-yield production and analysis of difficult-to-produce proteins
>80% success rate where other production systems failed
60+ collaborations, including 12 of 15 top pharma companies, resulting in multiple existing royalty-bearing partnerships plus broad wholly owned portfolio
Therapeutic equivalents, vaccines, antibody fragments, peptides, biosimilars, biobetters and other non-glycosylated proteins
Reduced manufacturing requirements drive competitive COGS
Broad intellectual property protection for platform and products with 22 issued US patents plus substantial know-how and trade secrets